合法化大麻时代的药物警戒:利用社交媒体监测免疫抑制剂与大麻衍生产品的药物相互作用
本研究通过检索Reddit上63,561,233条帖子,识别出190条同时讨论免疫抑制剂和大麻衍生产品(CDP)的帖子。两名盲法评估者发现66条(35%)表达了对潜在药物相互作用(DDI)的担忧,4条(2%)报告了独特的DDI,其中2条与Epidiolex首次报告的DDI相似。结论首次报告了消费者CDP(包括CBD和THC产品)与免疫抑制剂的DDI,强调需要加强监测和监管。
要点
- 社交媒体监测可发现临床试验无法捕获的消费者CDP与免疫抑制剂DDI信号。
- 35%相关帖子表达DDI担忧,2%报告独特DDI,包括CBD/西罗莫司、THC/西罗莫司和THC/他克莫司。
- 临床应主动询问移植患者免疫抑制剂使用期间CDP暴露情况。
核心结论
- 首次报告消费者大麻衍生产品(包括CBD和THC)与免疫抑制剂(他克莫司、西罗莫司)的DDI,可导致药物毒性。
- 需建立针对消费者CDP的药物安全信号监测体系并制定全面监管政策。
研究设计与样本
- 基于社交媒体的药物警戒案例研究,检索Reddit相关版块共63,561,233条帖子。
- 识别190条同时讨论免疫抑制剂和CDP的帖子,由两名盲法评估者独立评估DDI担忧和独特不良事件。
主要发现
- 66条帖子(35%)表达了对CDP与免疫抑制剂潜在DDI的担忧。
- 4条帖子(2%)报告了独特的DDI,其中2条与Epidiolex首次报告的DDI相似。
- 其余2条DDI包括潜在CBD/西罗莫司或THC/西罗莫司相互作用,以及THC/他克莫司相互作用,均导致药物毒性。
临床怎么用
- 临床药师应主动筛查使用免疫抑制剂的移植患者是否同时使用消费者CDP(包括CBD和THC产品)。
- 对报告CDP暴露的移植患者加强免疫抑制剂血药浓度监测和药物毒性预警。
局限性
- 数据来源于社交媒体帖子,存在自报告偏倚和无法验证的局限性。
- 仅检索Reddit平台,样本代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A clinical trial of Epidiolex®, the only US FDA-approved cannabis-derived consumer product (CDP), discovered an interaction with an immunosuppressant (tacrolimus) that led to drug toxicity, highlighting the unique intersection of prescription and commonly unregulated consumer products. OBJECTIVE: We aimed to identify if similar drug-drug interactions (DDIs) are occurring among the consumer CDP market, even though they cannot be identified through trials. METHODS: We searched Reddit for subreddits related to CDPs or health, resulting in 63,561,233 posts. From these, we identified 190 posts discussing both immunosuppressants and CDPs. Two blinded investigators evaluated the following. (1) Was there a concern about a potential DDI between consumer CDPs and immunosuppressants? (2) Was there a unique adverse event attributed to a DDI between consumer CDPs and immunosuppressants? RESULTS: Of these, 66 posts (35%) expressed concern about a potential DDI, such as "Hey, my partner wants to try my edibles … she's on Prograf [tacrolimus] and wants to talk to a stoner who's had a heart transplant." Four posts (2%) reported a unique DDI, such as "I have clinical results that are semi-anecdotal, showing the coordination to my halting substance use … It's the CBD. Shot my prograf to 30 at like 4 mg." Two of the four reported DDIs are similar to those first reported for Epidiolex. The remaining two reported DDIs include a potential cannabidiol (CBD)/sirolimus or delta-9-tetrahydrocannabinol (THC)/sirolimus interaction and a THC/tacrolimus interaction, both resulting in drug toxicity. CONCLUSION: This case study is the first to report on DDIs involving consumer CDPs, including both CBD and THC products, as well as a broader class of immunosuppressants. This demonstrates the risks associated with using consumer CDPs alongside prescription medications while highlighting the need for development of increased surveillance to monitor consumer CDPs for drug safety signals, as well as comprehensive regulations that take into account the unique characteristics of the consumer marketplace.
引用
- Allen MR, Wightman GP, Zhu Z, et al. Pharmacovigilance in the Age of Legalized Cannabis: Using Social Media to Monitor Drug-Drug Interactions Between Immunosuppressants and Cannabis-Derived Products. Drug Saf. 2024. PMID: 39292423. doi:10.1007/s40264-024-01481-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。